Sun Pharma to acquire rival Ranbaxy for $3.2bn

Mumbai-based Sun Pharmaceutical Industries is buying Indian rival Ranbaxy Laboratories in a merger worth $3.2 billion, the companies have confirmed.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

AstraZeneca partners with Chinese firm ahead of next obesity race

5 February 2026 The British-Swedish pharma giant pays $1.2 billion upfront for access to next-generation weight-loss treatment as China patent cliff changes the market.

Asia

Chinese biotech strikes billion dollar deal in nextgen cancer race

20 January 2026 Magic Circle and major US firm among dealmakers who worked on the licensing agreement for a bispecific antibody candidate, marking another significant outbound licensing deal from China’s biopharma sector.

Asia

Novo Nordisk secures China win ahead of key patent expiration

6 January 2026 Danish pharma giant notches an important victory in a huge market for semaglutide, but faces a patent cliff and mounting challenges across India, Canada and the US.

More features

SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling

Eli Lilly escapes $278m payout in biotech licensing dispute

Novo battles for GLP-1 leadership with fresh lawsuit and slashed prices

Wiggin’s new litigation partner deepens ‘technically complex’ offer

Could everyday hospital equipment be the next defence against counterfeit medicines?

BioNTech fires shots at Moderna's next-generation vaccine

Mintz gains ex-Winston & Strawn partner and ITC expert

Abbott unit defends European protection for heart valve ‘cuff’ design

Sun Pharma to acquire rival Ranbaxy for $3.2bn

More on this story

Editor's picks

Editor's picks

More features